|This report containsCOVID-19specific updates.DNA疫苗：技术和全球市场
Report Highlights
全球DNA疫苗市场应从2021年的31亿美元增长到2026年的115亿美元，在2021 - 2026年期间，复合年增长率（CAGR）为30.1％。
Report Includes
- 14 data tables and 55 additional tables
- An overview of the global market for DNA vaccines and related technologies
- Analyses of global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Coverage of delivery and synthesis technologies, the forces driving market growth, product formats, and market applications for these products
- Identification of new opportunities, challenges, and technological changes within the industry and highlights of the market potential for DNA vaccines by delivery technology, format, function and region
- Coverage of life cycle status and commercial status of DNA vaccine technologies and brief description of the Human Immune System
- Details about vaccines, their evolution, and types including DNA vaccines and cancer DNA vaccines, their function, scope and clinical trials, and information on changing vaccine paradigm, antigen discovery, plasmid design and manufacture and delivery technologies
- Detailed analysis of the current market trends, market forecast, and discussion of technological, and regulatory elements that are affecting the future marketplace
- Information about major technologies for the formulation of DNA vaccines and assessment of their relation to biotechnology, gene therapy, DNA delivery, pharmaceuticals, and biodefense companies
- Comprehensive profiles of leading companies in the field as well as updates to alliance, merger, and acquisition activities, including Astellas Pharma Inc., Bristol-Myers Squibb Co., Merck & Co., Novartis AG, Pfizer Inc. and Sanofi-Aventisa
Report Scope
The study’s scope includes DNA vaccine products that already are commercialized or likely to be in the next five years. Both human and animal health markets are studied. DNA vaccine delivery technologies are also included. DNA vaccine candidates in clinical trials are examined by indication, and future market growth from 2021 through 2026 is forecast.
The role that DNA vaccines play in the overall vaccine industry is examined, as well as how the vaccine industry structure and dynamics are changing.
We examine DNA synthesis, biotechnology and pharmaceuticals firms, strategic industry alliances, and the role of gene delivery and synthesis technologies. The major markets for DNA vaccines, including infectious diseases, cancers, animal health, allergies and biodefense, are analyzed, and the main companies in these fields are highlighted.
Analyst Credentials
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
Report Highlights
The global market for DNA vaccines was valued at $243.7 million in 2013 and is expected to increase to $305.3 million in 2014, and further to $2.7 billion by 2019, a compound annual growth rate (CAGR) of 54.8% over the five-year period from 2014 through 2019.
Report Includes
- An overview of the global market for DNA vaccines and related technologies.
- Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
- Details concerning delivery and synthesis technologies, the forces driving market growth, product formats, and market applications for these products.
- Information most useful forbiotechnology, DNA plasmid, gene therapy, DNA delivery, pharmaceutical, vaccine, animal health, and biodefense companies.
- Comprehensive profiles of leading companies in the field as well as updates to alliance, merger, and acquisition activity.
Report Highlights
- Overall sales in the DNA vaccines market were worth $141 million in 2008, and increased to an estimated $193 million in 2009. By 2014, it is projected to increase substantially to $2.7 billion, for a 5-year compound annual growth rate (CAGR) of 69.5%.
- The human health vaccine segment was valued at $12 million in 2008. This is expected to increase to nearly $24 million in 2009, and is projected to reach almost $2.3 billion in 2014, for a 5-year CAGR of 149.6%.
- Sales in the research tools segment amounted to $73 million in 2008, increased to nearly $92 million in 2009, and are projected to reach nearly $166 million in 2014, for a 5-year CAGR of 12.6%.